mutations and sophisticated kar yotype. It follows a linear evolution in the CLL clone through the recurrent acquisition of CDKN2AGenetic susceptibility mechanisms. Most susceptibility loci map to non-coding locations with the genome, are largely located in Lively promoters or enhancers, and modify the binding websites of several transcription aspe